Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
A phase 3 trial of Somatostatin analogues and Pegvisomant in Pituitary tumours, run by Ipsen, completed.
Overview
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients is a phase 3 interventional study registered as NCT00383708 by Ipsen, with 125 participants recorded, started 2006-10 and reaching its primary completion in 2008-10. Interventions recorded: lanreotide (Autogel formulation), Pegvisomant. Conditions recorded: Acromegaly.
Linked to the drug Pegvisomant because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStrict IGF-1 Control in Acromegaly
Shares Pegvisomant, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialLong Term Study With B2036-PEG
Shares Pegvisomant, Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialSafety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
Shares Somatostatin analogues (octreotide, lanreotide), Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Ipsen and the tag pipeline.
- TrialA Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Shares Ipsen and the tag pipeline.
- TrialA Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Shares Ipsen and the tag pipeline.
- TrialA Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Shares Ipsen and the tag pipeline.
- TrialEffect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer
Shares Ipsen and the tag pipeline.